On Friday, Shares of Horizon Pharma plc (NASDAQ:HZNP), gained 3.91% to $29.22.
Horizon Pharma, named John B. Thomas executive vice president, strategy and investor relations, reporting directly to Timothy P. Walbert, chairman, president and chief executive officer, effective right away. Thomas will join the Company’s Executive Committee and will lead the Company’s investor relations function and oversee corporate strategy development.
Thomas is the former vice president of investor relations and public affairs for Abbott, where he counseled the senior executive team on the financial community’s expectations regarding major acquisitions, divestitures, planned partnerships, research and development and ongoing business performance. He is also former president of the Abbott Fund, where he led investment in programs that make lasting changes in people’s lives, counting access to health care, science education and community-based nutrition and health initiatives.
Preceding to joining Abbott, Thomas was manager of corporate communications for Mallinckrodt Veterinary and Budget Rent-A-Car. Before that, he was an award-winning health and education senior editor and staff writer at Meredith Corporation.
Thomas graduated cum laude from The University of Mississippi with a bachelor’s degree in journalism and a minor in English. He also holds a master’s degree in business administration from The Lake Forest Graduate School of Administration.
Horizon Pharma plc, a specialty biopharmaceutical company, engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally.
At the end of Friday’s trade, Shares of Newell Rubbermaid Inc. (NYSE:NWL), jumped 3.88% to $39.61.
Newell Rubbermaid, declared its first quarter 2015 financial results.
First Quarter 2015 Operating Results
Net sales in the first quarter were $1.26 billion contrast with $1.21 billion in the preceding year. Core sales grew 4.7 percent, not taking into account a 490 basis point net contribution from acquisitions and planned divestitures and a 550 basis point negative impact from foreign currency.
Stated gross margin was 38.6 percent, a 100 basis point improvement as compared to preceding year.
Normalized gross margin was 38.8 percent, a 50 basis point improvement as compared to preceding year, as benefits from productivity, commodity deflation and pricing more than offset the negative impacts of foreign currency and mix from acquisitions.
First quarter stated operating margin was 7.8 percent and operating income was $98.2 million, contrast with 8.6 percent and $104.7 million, respectively, in the preceding year.
Normalized operating margin of 12.1 percent was a 90 basis point improvement contrast with the preceding year, despite a 50 basis point enhance in advertising and promotion. Normalized operating income was $152.6 million contrast with $135.4 million in the preceding year.
The stated tax rate for the quarter was 27.9 percent contrast with a 3.0 percent benefit in the preceding year. The normalized tax rate was 27.2 percent contrast with 18.3 percent in the preceding year.
Normalized net income was $97.0 million, contrast with $97.8 million in the preceding year. Normalized diluted earnings per share were $0.36, an enhance of 5.9 percent as compared to $0.34 in the preceding year. The improvement in normalized diluted earnings per share was attributable to raised core sales, gross margin expansion, contribution from acquisitions and the positive impact of fewer outstanding shares, which more than offset a noteworthy enhance in advertising and promotion support, negative foreign currency impacts, a higher tax rate and raised interest expense related to borrowing in support of last year’s acquisitions.
Stated diluted earnings per share were $0.20, contrast with $0.19 per diluted share in the preceding year. Stated net income was $54.1 million, contrast with $52.9 million in the preceding year. In addition to the factors cited in the explanation of normalized diluted earnings per share, stated diluted earnings per share were negatively influenced by higher incremental restructuring and other project costs of $22.5 million in 2015, and favorably influenced by the absence of a 2014 $38.7 million charge associated with the devaluation of the Venezuelan bolivar.
Newell Rubbermaid Inc. manufactures and markets consumer and commercial products worldwide. It operates through five segments: Writing, Home Solutions, Tools, Commercial Products, and Baby & Parenting.
Cempra, Inc. (NASDAQ:CEMP), ended its last trade with 3.84% gain, and closed at $32.70.
Cempra, stated financial results for the quarter ended March 31, 2015 and offered an update on recent corporate developments. The company will host a webcast and conference call recently at 4:30 p.m. EDT.
First Quarter 2015 and Recent Corporate Highlights
- In April 2015, investigators presented abstracts and select data from clinical and scientific studies of solithromycin at the European Congress of Clinical Microbiology (ECCMID) in Copenhagen, Denmark. Two studies with Taksta(TM) (fusidic acid) were also presented. Additionally, Cempra made a presentation on solithromycin at the 2015 Pediatric Academic Societies (PAS) Annual Meeting in San Diego. This pediatric study was funded by BARDA (Biomedical Advanced Research Development Authority).
- A Phase 1b clinical trial in newborn to 17 year old pediatric patients began during the first quarter with funding from BARDA. The study is designed to enroll patients who will receive oral capsules, oral suspension or IV dosage forms of solithromycin. This program represents the first development of a pediatric suspension formulation of an antibiotic for respiratory tract infections in over 20 years.
- In January 2015, Cempra stated positive topline results from Solitaire-Oral, a global, pivotal Phase 3 clinical trial of solithromycin oral capsules in community attained bacterial pneumonia (CABP). Solithromycin met the primary objective of statistical non-inferiority of the early clinical response at 72 hours after initiation of therapy contrast to moxifloxacin in the intent-to-treat (ITT) population. Solithromycin also met the secondary objectives of non-inferiority in clinical success at the short term follow up visit, 5-10 days after the end of therapy in the ITT, mITT (ITT population with microbial isolates) and clinically evaluable populations.
- Cempra accomplished a public offering of 6,037,500 shares of common stock in January 2015 at $24.50 per share, inclusive of the full exercise by the underwriters to purchase additional shares at the public offering price. Net proceeds from the offering totaled $138.8 million after underwriting discounts and commissions and other offering expenses.
Cempra, Inc., a clinical-stage pharmaceutical company, focuses on developing antibiotics to meet medical needs in the treatment of bacterial infectious diseases in North America. Its lead product candidates comprise solithromycin (CEM-101), which is in Phase III clinical trials for the treatment of community attained bacterial pneumonia.
Finally, Tower Semiconductor Ltd. (NASDAQ:TSEM), closed at $15.15, with 3.84% gain.
TowerJazz , a part of Tower Semiconductor, will issue its first quarter 2015 earnings release on Wednesday, May 13, 2015. The Company will hold a conference call to talk about its first quarter 2015 financial results and second quarter 2015 guidance on Wednesday, May 13, 2015, at 10:00 a.m. Eastern Time (09:00 a.m. Central, 08:00 a.m. Mountain, 07:00 a.m. Pacific and 05:00 p.m. Israel time).
Tower Semiconductor Ltd., an independent semiconductor foundry, manufactures analog intensive mixed-signal semiconductor devices in the United States, Asia, and Europe. It produces integrated circuits (IC) primarily based on third party designs and proprietary designs with geometries ranging from 1.0 to 0.11 micron, in addition to provides design and technical services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
